Emergent Biosolutions EBS Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's amortization expense related to capitalized debt issuance costs?
- Emergent Biosolutions (EBS) reported amortization expense related to capitalized debt issuance costs of $1.8M in Q1 2026.
- How has Emergent Biosolutions's amortization expense related to capitalized debt issuance costs changed year-over-year?
- Emergent Biosolutions's amortization expense related to capitalized debt issuance costs decreased by 21.7% year-over-year, from $2.3M to $1.8M.
- What is the long-term trend for Emergent Biosolutions's amortization expense related to capitalized debt issuance costs?
- Over 3 years (2021 to 2025), Emergent Biosolutions's amortization expense related to capitalized debt issuance costs has grown at a 33.7% compound annual growth rate (CAGR), from $4.1M to $9.8M.